Sevasemten
Targeting contraction-induced muscle injury
We developed sevasemten with the aim to address the root cause of muscle breakdown in muscular dystrophies, contraction-induced muscle damage. All muscles contract during daily activities.
In muscular dystrophies, the muscle lacks protective components including the fully functional protein dystrophin. When muscle fibers are not protected and unstable, contraction-induced injury starts a repetitive cycle that ultimately leads to fat and scar and fibrosis in the muscle, and loss of function
Contraction-Induced Muscle Damage in Muscular Dystrophies
Healthy Muscle
Dystrophic Muscle
About Sevasemten
Investigational therapy for Becker and Duchenne
Sevasemten is an orally administered first-in-class fast skeletal myosin inhibitor designed to protect unstable muscle against contraction-induced muscle damage in muscular dystrophies including Becker and Duchenne.
Designed to preserve and protect fast muscle fibers
By minimizing the progressive muscle damage that leads to functional impairment, sevasemten has the potential to benefit a broad range of patients suffering from debilitating skeletal muscle disorders either as a single agent therapy or in combination with available therapies and those in development.
Clinical trials of sevasemten in Becker and Duchenne are ongoing
Sevasemten is currently in late-stage clinical trials with investigational study sites across the globe.
Watch sevasemten in real-time
Dr. Alan Russell, Edgewise Co-founder and Chief Scientific Officer, explains how sevasemten protects dystrophic muscle from damage in an animal model of Duchenne.
Sevasemten is an investigational therapy that has not been approved for use in Becker muscular dystrophy or Duchenne muscular dystrophy by any regulatory agency, as its safety and effectiveness have not been established for the treatment of these diseases.
